This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains to many pages, the maxiumum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

John Hurvitz
John A. Hurvitz
Partner
Washington +1 202 662 5319 jhurvitz@cov.com Download V-card

John Hurvitz co-chairs Covington's Life Sciences Industry Group, heads the firm's Technology Transactions Group and is vice-chair of the firm’s Corporate Group.

Mr. Hurvitz is a trusted advisor to both established and emerging life sciences companies, providing not only transactional counsel but also strategic advice with respect to business development, asset management, performance enhancement, dispute resolution under existing collaborations, industry best practices and other benchmarking advice.  His clients and deal experience extend throughout the United States, Europe and Asia as well to emerging markets and include all segments of the industry—pharma, biotech, medtech, diagnostics, animal health, vaccines and health services.

  • Merck in connection with the sale of its Consumer Care Business to Bayer AG for $14.2 billion. 
  • AbbVie in a novel collaboration with the Google-backed life sciences start-up company Calico focused on aging and age-related diseases, such as cancer and neurodegenerative diseases.
  • Regeneron in an agreement with Bayer Healthcare to jointly develop an innovative antibody for the treatment of wet age-related macular degeneration (wet AMD), the leading cause of blindness in the elderly.
  • Millennium: The Takeda Oncology Company in a collaboration agreement with Mersana to develop next-generation antibody-drug conjugates (ADCs) using Mersana’s proprietary Fleximer technology.
  • AstraZeneca in its global agreement with Pfizer to switch AstraZeneca’s blockbuster GI drug, Nexium, to over-the-counter, which involved an upfront payment of $250 million as well a right of first refusal to switch another of AstraZeneca’s Rx Products.
  • Eli Lilly in its agreement to terminate its alliance with Amylin Pharmaceuticals for Byetta and Bydureon and to resolve the outstanding litigation between the companies, involving a two-year transition of responsibilities outside the US and payments of up to $1.6 billion.
  • AstraZeneca in an agreement with Moderna Therapeutics to develop and commercialize pioneering messenger RNA therapeutics for the treatment of serious cardiovascular, metabolic, and renal diseases, as well as cancer, which involved an upfront payment of $240 million and up to an additional $180 million in technical milestones.
  • Eisai in an agreement with Epizyme and Roche Molecular Systems to collaborate on the development of a companion diagnostic to advance personalized therapeutics for patients with lymphomas possessing genetic mutations in the epigenetic enzyme EZH2.
  • Takeda in its acquisition of Intellikine, a privately-held company focused on the discovery and development of innovative, small molecule drugs, for $190 million at closing and up to $120 million in additional potential clinical development milestone payments.
  • AstraZeneca in its agreement with Ironwood Pharmaceuticals, Inc. to develop and market Ironwood’s linaclotide in China.
  • AstraZeneca in its strategic diabetes alliance with Bristol-Myers Squibb in connection with BMS’s acquisition of Amylin Pharmaceuticals in a deal valued at $7 billion (approximately half the cost of which was borne by AZ).
  • Abbott Laboratories in its $3.7 billion acquisition of Kos Pharmaceuticals, Inc.
  • Medarex on its $2.4 billion merger with Bristol-Myers Squibb.
  • King Pharmaceuticals in its $3.6 billion merger with Pfizer Inc.
  • Boehringer Ingelheim Vetmedica in its acquisition of certain animal health products divested by Wyeth and Pfizer Inc. pursuant to an FTC consent order entered into in connection with Pfizer Inc.’s acquisition of Wyeth.
  • Chambers USA, recognized for Life Sciences Corporate/Commercial (Band 1)
  • Chambers Global, recognized as a leading lawyer for Life Sciences Corporate/Commercial
  • Washington DC Super Lawyers   
  • Best Lawyers in America, recognized for FDA
  • Law360, Life Sciences “MVP”   
  • Who's Who Legal, Life Sciences – Transactional
  • Legal 500 US, “Leading Lawyer” – Healthcare: Life Sciences
  • PLC Which Lawyer?, consistently recognized as a "leading commercial and partnering" lawyer, and one of only five "leading" corporate partnering lawyers in the US.
  • LMG Life Sciences, “Life Science Star”
  • IAM Patent 1000 - The World’s Leading Patent Practitioners